EA201200329A2 - Ингибиторы мет для повышения эффективности лучевой терапии - Google Patents

Ингибиторы мет для повышения эффективности лучевой терапии

Info

Publication number
EA201200329A2
EA201200329A2 EA201200329A EA201200329A EA201200329A2 EA 201200329 A2 EA201200329 A2 EA 201200329A2 EA 201200329 A EA201200329 A EA 201200329A EA 201200329 A EA201200329 A EA 201200329A EA 201200329 A2 EA201200329 A2 EA 201200329A2
Authority
EA
Eurasian Patent Office
Prior art keywords
met
monoclonal anti
improve efficiency
antibody
cdr
Prior art date
Application number
EA201200329A
Other languages
English (en)
Other versions
EA201200329A3 (ru
EA028590B1 (ru
Inventor
Карла Боккаччо
Паоло Мария Комольо
Фиорелла Петронцелли
Рита Де Сантис
Original Assignee
Метерезис Транслейшнл Ресерч Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метерезис Транслейшнл Ресерч Са filed Critical Метерезис Транслейшнл Ресерч Са
Publication of EA201200329A2 publication Critical patent/EA201200329A2/ru
Publication of EA201200329A3 publication Critical patent/EA201200329A3/ru
Publication of EA028590B1 publication Critical patent/EA028590B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Ингибитор Met и/или нуклеотидная последовательность, кодирующая ингибитор Met, для применения при лечении пациентов, страдающих злокачественной опухолью, для снижения и/или отмены устойчивости пациента к лучевой терапии, где ингибитор Met выбран из: i) моноклонального анти-Met антитела, ii) генетически сконструированного антитела, содержащего определяющие комплементарность области (CDR) моноклонального анти-Met антитела, и iii) фрагмента (i) или (ii), содержащего определяющие комплементарность области (CDR) моноклонального анти-Met антитела, или их сочетания.
EA201200329A 2011-03-18 2012-03-16 Ингибиторы мет для повышения эффективности лучевой терапии EA028590B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11158861.2A EP2500036B1 (en) 2011-03-18 2011-03-18 MET inhibitors for enhancing radiotherapy efficacy
EP11158861.2 2011-03-18

Publications (3)

Publication Number Publication Date
EA201200329A2 true EA201200329A2 (ru) 2012-09-28
EA201200329A3 EA201200329A3 (ru) 2013-01-30
EA028590B1 EA028590B1 (ru) 2017-12-29

Family

ID=44260211

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200329A EA028590B1 (ru) 2011-03-18 2012-03-16 Ингибиторы мет для повышения эффективности лучевой терапии

Country Status (23)

Country Link
US (1) US20120237524A1 (ru)
EP (1) EP2500036B1 (ru)
JP (1) JP5671487B2 (ru)
KR (1) KR101540838B1 (ru)
CN (1) CN102688491A (ru)
AU (1) AU2012201303B2 (ru)
BR (1) BR102012006063B1 (ru)
CA (1) CA2769991C (ru)
CY (1) CY1115374T1 (ru)
DK (1) DK2500036T3 (ru)
EA (1) EA028590B1 (ru)
ES (1) ES2489475T3 (ru)
HK (1) HK1174539A1 (ru)
HR (1) HRP20140729T1 (ru)
IL (1) IL218293A (ru)
MX (1) MX2012003084A (ru)
PL (1) PL2500036T3 (ru)
PT (1) PT2500036E (ru)
RS (1) RS53468B (ru)
SG (1) SG184637A1 (ru)
SI (1) SI2500036T1 (ru)
SM (1) SMT201400106B (ru)
ZA (1) ZA201201992B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN110320365B (zh) * 2019-07-06 2022-07-22 湖南莱拓福生物科技有限公司 NF-κB RelA/p65蛋白位点特异性磷酸化诊断试剂盒
CN114340684A (zh) 2019-09-16 2022-04-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
EP1592713A2 (en) * 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
TW201319088A (zh) * 2003-07-18 2013-05-16 Amgen Inc 對肝細胞生長因子具專一性之結合劑
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
MX2008009833A (es) * 2006-02-06 2008-10-23 Metheresis Translational Res S Anticuerpo monoclonal anti-met, fragmentos y vectores del mismo para el tratamiento de tumores, y productos correspondientes.
EP2019116A1 (en) * 2007-07-26 2009-01-28 Helmholtz-Zentrum für Infektionsforschung GmbH Inhibitor of the met-receptor and its use

Also Published As

Publication number Publication date
DK2500036T3 (da) 2014-08-04
EP2500036B1 (en) 2014-05-07
JP5671487B2 (ja) 2015-02-18
IL218293A0 (en) 2012-07-31
IL218293A (en) 2016-06-30
RS53468B (en) 2014-12-31
US20120237524A1 (en) 2012-09-20
PT2500036E (pt) 2014-08-25
BR102012006063B1 (pt) 2023-03-07
JP2012196206A (ja) 2012-10-18
CN102688491A (zh) 2012-09-26
CA2769991C (en) 2018-05-15
CA2769991A1 (en) 2012-09-18
SG184637A1 (en) 2012-10-30
EA201200329A3 (ru) 2013-01-30
HK1174539A1 (en) 2013-06-14
SMT201400106B (it) 2014-11-10
ES2489475T3 (es) 2014-09-02
KR20120106582A (ko) 2012-09-26
KR101540838B1 (ko) 2015-08-06
BR102012006063A8 (pt) 2022-11-08
BR102012006063A2 (pt) 2021-11-16
AU2012201303A1 (en) 2012-10-04
HRP20140729T1 (hr) 2014-08-29
CY1115374T1 (el) 2017-01-04
EP2500036A1 (en) 2012-09-19
PL2500036T3 (pl) 2014-10-31
ZA201201992B (en) 2015-05-27
AU2012201303B2 (en) 2013-11-07
SI2500036T1 (sl) 2014-09-30
MX2012003084A (es) 2012-09-17
EA028590B1 (ru) 2017-12-29

Similar Documents

Publication Publication Date Title
CY1121148T1 (el) Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων
EA201200329A3 (ru) Ингибиторы мет для повышения эффективности лучевой терапии
EA201490230A1 (ru) Применение меченых ингибиторов hsp90
NZ706986A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
EA200970335A1 (ru) Композиции и способы для диагностики и лечения рака
MX349198B (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
RU2014108042A (ru) Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
EA201390550A1 (ru) Способы ингибирования пролиферации клеток в egfr-стимулируемых злокачественных опухолях
EA201490814A1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
RU2014108044A (ru) Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
UA94899C2 (ru) Фиксированное дозирование антител к her
RU2014108045A (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
RU2014108043A (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
NZ601580A (en) Therapeutic methods using anti-cd200 antibodies
IN2015KN00350A (ru)
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
JP2015517300A5 (ru)
EA202092276A3 (ru) Антитело, распознающее лейкемический ингибиторный фактор (lif) человека, и применение антител против lif при лечении заболеваний, связанных с нежелательной пролиферацией клеток
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
WO2011146568A8 (en) Predicting response to a her inhibitor
NZ603191A (en) Methods for the treatment of il-1b related conditions
MX2013009732A (es) Terapias de combinacion comprendiendo agentes anti-erbb3.
PH12016500578A1 (en) Treatment for neoplastic diseases
MX2012010212A (es) Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer.
NZ595755A (en) Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM